Aska Pharmaceutical Signs License With Sosei On Emergency Contraception Drug
This article was originally published in PharmAsia News
Aska Pharmaceutical signed a license agreement with Sosei Oct. 21 and obtained exclusive rights to market SOH-075, an emergency contraception pill Sosei in-licensed from French Laboratoire HRA Pharma. SOH-075 completed Phase III trials in Japan and an approval is expected by the early half of 2009. According to the agreement, Sosei will receive a ¥300 million upfront payment, as well as potential milestone and royalty payments. Sosei will apply for the new drug approval and Aska will market the drug and conduct post-market surveillance. (Click here for more - Japanese language
You may also be interested in...
Tokyo-based biopharmaceutical firm Sosei submitted an NDA for Norlevo (levonorgestrel), Japan's first emergency contraceptive pill. The filing puts Japan one step further to joining a list of 60 countries that have approved the so called "Plan B" or "morning-after pill.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.